Managing urinary incontinence in women - a review of new and emerging pharmacotherapy

Riccardo Bientinesi, Emilio Sacco

Research output: Contribution to journalReview article

Abstract

Introduction: The pharmacological treatment of urinary incontinence and overactive bladder (OAB) has been, for a longer time, based on antimuscarinic agents. In recent years, two other pharmacological principles have been introduced for the treatment of OAB and urgency urinary incontinence: the β3-adrenergic agent mirabegron and botulinum neurotoxin. Meanwhile, there is lack of effective drugs for the treatment of stress incontinence. Areas covered: This literature review presents synthetic compounds aimed to treat female urinary incontinence that are in phase II-III clinical development. Expert opinion: Antimuscarinic agents will continue to represent the current gold standard for the first-line pharmacological management of OAB and urgency urinary incontinence. The class of β3-agonists will certainly expand with the discovery and clinical development of novel agents. Combination therapy of antimuscarinic agents and β3-agonists could offer an alternative treatment in these patients, including those with symptoms refractory to first-line monotherapy. A huge number of preclinical studies are underway in this field exploring the therapeutic potential of many novel compounds while some have advanced to clinical phases of development.

Original languageEnglish
Pages (from-to)1989-1997
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume19
Issue number18
DOIs
Publication statusPublished - Dec 12 2018

Fingerprint

Urinary Incontinence
Drug Therapy
Overactive Urinary Bladder
Muscarinic Antagonists
Pharmacology
Therapeutics
Neurotoxins
Expert Testimony
Adrenergic Agents
Urinary Bladder
Pharmaceutical Preparations

Keywords

  • female urinary incontinence
  • overactive bladder
  • Pharmacological therapy
  • urinary incontinence

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Managing urinary incontinence in women - a review of new and emerging pharmacotherapy. / Bientinesi, Riccardo; Sacco, Emilio.

In: Expert Opinion on Pharmacotherapy, Vol. 19, No. 18, 12.12.2018, p. 1989-1997.

Research output: Contribution to journalReview article

@article{3c9aead2b8c9490ca5ceca57355581e6,
title = "Managing urinary incontinence in women - a review of new and emerging pharmacotherapy",
abstract = "Introduction: The pharmacological treatment of urinary incontinence and overactive bladder (OAB) has been, for a longer time, based on antimuscarinic agents. In recent years, two other pharmacological principles have been introduced for the treatment of OAB and urgency urinary incontinence: the β3-adrenergic agent mirabegron and botulinum neurotoxin. Meanwhile, there is lack of effective drugs for the treatment of stress incontinence. Areas covered: This literature review presents synthetic compounds aimed to treat female urinary incontinence that are in phase II-III clinical development. Expert opinion: Antimuscarinic agents will continue to represent the current gold standard for the first-line pharmacological management of OAB and urgency urinary incontinence. The class of β3-agonists will certainly expand with the discovery and clinical development of novel agents. Combination therapy of antimuscarinic agents and β3-agonists could offer an alternative treatment in these patients, including those with symptoms refractory to first-line monotherapy. A huge number of preclinical studies are underway in this field exploring the therapeutic potential of many novel compounds while some have advanced to clinical phases of development.",
keywords = "female urinary incontinence, overactive bladder, Pharmacological therapy, urinary incontinence",
author = "Riccardo Bientinesi and Emilio Sacco",
year = "2018",
month = "12",
day = "12",
doi = "10.1080/14656566.2018.1532502",
language = "English",
volume = "19",
pages = "1989--1997",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "18",

}

TY - JOUR

T1 - Managing urinary incontinence in women - a review of new and emerging pharmacotherapy

AU - Bientinesi, Riccardo

AU - Sacco, Emilio

PY - 2018/12/12

Y1 - 2018/12/12

N2 - Introduction: The pharmacological treatment of urinary incontinence and overactive bladder (OAB) has been, for a longer time, based on antimuscarinic agents. In recent years, two other pharmacological principles have been introduced for the treatment of OAB and urgency urinary incontinence: the β3-adrenergic agent mirabegron and botulinum neurotoxin. Meanwhile, there is lack of effective drugs for the treatment of stress incontinence. Areas covered: This literature review presents synthetic compounds aimed to treat female urinary incontinence that are in phase II-III clinical development. Expert opinion: Antimuscarinic agents will continue to represent the current gold standard for the first-line pharmacological management of OAB and urgency urinary incontinence. The class of β3-agonists will certainly expand with the discovery and clinical development of novel agents. Combination therapy of antimuscarinic agents and β3-agonists could offer an alternative treatment in these patients, including those with symptoms refractory to first-line monotherapy. A huge number of preclinical studies are underway in this field exploring the therapeutic potential of many novel compounds while some have advanced to clinical phases of development.

AB - Introduction: The pharmacological treatment of urinary incontinence and overactive bladder (OAB) has been, for a longer time, based on antimuscarinic agents. In recent years, two other pharmacological principles have been introduced for the treatment of OAB and urgency urinary incontinence: the β3-adrenergic agent mirabegron and botulinum neurotoxin. Meanwhile, there is lack of effective drugs for the treatment of stress incontinence. Areas covered: This literature review presents synthetic compounds aimed to treat female urinary incontinence that are in phase II-III clinical development. Expert opinion: Antimuscarinic agents will continue to represent the current gold standard for the first-line pharmacological management of OAB and urgency urinary incontinence. The class of β3-agonists will certainly expand with the discovery and clinical development of novel agents. Combination therapy of antimuscarinic agents and β3-agonists could offer an alternative treatment in these patients, including those with symptoms refractory to first-line monotherapy. A huge number of preclinical studies are underway in this field exploring the therapeutic potential of many novel compounds while some have advanced to clinical phases of development.

KW - female urinary incontinence

KW - overactive bladder

KW - Pharmacological therapy

KW - urinary incontinence

UR - http://www.scopus.com/inward/record.url?scp=85058554339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058554339&partnerID=8YFLogxK

U2 - 10.1080/14656566.2018.1532502

DO - 10.1080/14656566.2018.1532502

M3 - Review article

C2 - 30304645

AN - SCOPUS:85058554339

VL - 19

SP - 1989

EP - 1997

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 18

ER -